539561 SUPHA

Supha Pharmachem Share Price

 

 

Start SIP in SUPHA

Start SIP
Supha Pharmachem live price: ₹0.45.

Supha Pharmachem Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹2
  • Open Price₹0
  • Previous Close₹0
  • Volume9,668,746
  • 50 DMA₹0.77
  • 100 DMA₹0.94
  • 200 DMA₹1.52

Investment Returns

  • Over 1 Month -50.55%
  • Over 3 Month -50%
  • Over 6 Month -70.39%
  • Over 1 Year -71.52%

Smart Investing Starts Here Start SIP with Supha Pharmachem for Steady Growth!

Invest Now

Supha Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -18.3
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 40
  • P/B Ratio
  • 0.4
  • Average True Range
  • 0.05
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.09
  • RSI
  • 21.38
  • MFI
  • 21.9

Supha Pharmachem Financials

Supha Pharmachem Technicals

EMA & SMA

Current Price
₹0.45
-0.02 (-4.26%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹0.62
  • 50 Day
  • ₹0.77
  • 100 Day
  • ₹0.94
  • 200 Day
  • ₹1.52

Resistance and Support

0.45 Pivot Speed
  • R3 0.45
  • R2 0.45
  • R1 0.45
  • S1 0.45
  • S2 0.45
  • S3 0.45

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Supha Pharmachem has an operating revenue of Rs. 629.68 Cr. on a trailing 12-month basis. An annual revenue de-growth of -94% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 4% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 31 indicates it belongs to a strong industry group of Leisure-Products and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Supha Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-03-30 Quarterly Results (Revised) to consider 1. Letter of Offer for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders. 2. Other business matters.
2025-11-14 Quarterly Results
2025-09-22 Rights Issue & Others To consider 1. Increase in Authorised Capital. to consider 1. Letter of Offer for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders. 2. Other business matters.
2025-08-04 Quarterly Results
2025-05-30 Audited Results
Date Purpose Remarks
2024-02-23 Split Rs.0.00 split from Rs. 5/- to Re. 1/-..
2023-09-01 Split Rs.0.00 split from Rs. 10/- to Rs. 5/-.
Date Purpose Remarks
2024-07-06 Bonus Rs.0.00 issue of equity shares in the ratio of 3:1 of Rs. 10/-.
2023-07-29 Bonus Rs.0.00 issue of equity shares in the ratio of 9:5 of Rs. 10/-.

Supha Pharmachem F&O

Supha Pharmachem Shareholding Pattern

1.13%
1.7%
81.29%
15.88%

Supha Pharmachem FAQs

Supha Pharmachem share price is ₹0 As on 15 March, 2026 | 20:01

The Market Cap of Supha Pharmachem is ₹39.7 Cr As on 15 March, 2026 | 20:01

The P/E ratio of Supha Pharmachem is -18.3 As on 15 March, 2026 | 20:01

The PB ratio of Supha Pharmachem is 0.4 As on 15 March, 2026 | 20:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23